Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy

SpringerPlus

Table 1 Staining results of each samples

		ER	PgR	Ki67	BRCA1		AR		IGF1Rb	P13K		AKT		pAKT		TUNEL	HER2	Fas	TGFßR1	GF1Rb
Patient		nuc	nuc	nuc	nuc	cyto	nuc	cyto	cyto	nuc	cyto	nuc	cyto	nuc	cyto	m	m	m	m	m
1	pre	158	8	10	121	0	94	0	80	0	46	18	95	5	90	25	1	0	0	3
1	post	120	10	10	106	95	5	60	70	0	56	0	90	5	0	0	1	10	1	1
2	pre	156	0	20	97	0	124	50	80	0	106	10	42	0	0	0	1	0	2	1
2	post	110	137	40	4	0	3	0	0	0	109	46	85	0	0	9	1	0	1	3
3	pre	140	6	20	55	0	111	0	90	0	100	105	0	0	40	6	1	0	1	3
3	post	0	30	50	39	0	5	0	100	0	100	31	0	133	90	6	3	0	1	1
4	pre	156	17	10	116	0	106	0	0	0	88	40	90	0	0	0	1	0	0	1
	during	11	203	20	122	0	18	95	0	0	100	85	100	0	0	0	1	0	0	2
	post	10	122	30	100	100	15	98	0	0	100	95	95	0	0	3	0	0	1	2
5	pre	172	0	5	100	0	128	0	0	0	15	0	95	16	90	2	2	0	2	1
	pre	198	0	3	100	0	109	0	70	0	100	10	80	5	0	0	1	0	1	1
	pre	117	0	20	101	0	88	0	0	0	100	90	90	0	24	9	1	0	1	1
	pre	162	0	15	98	0	112	0	85	0	100	70	90	0	0	3	1	0	1	1
	pre	203	0	10	98	0	120	0	20	0	80	50	80	0	15	0	1		1	1
	during	89	141	5	45	0	101	100	90	0	95	19	60	0	0	0	2	0	1	1
	post	103	0	20	98	98	100	98	0	0	100	19	95	0	95	0	2	0	1	1
6	pre	205	161	10	80	0	200	90	100	0	98	50	90	46	0	6	1	0	1	3
6	during	104	170	5	5	0	107	99	0	0	100	3	90	0	0	6	1	0	1	1

Nuclear and cytosolic staining were evaluated by HistoScore. Membrance staining was clasiffied as 0, 1+, 2+ and 3+ following the recommendations for Her2 staining.
nuc: nuclear, cyto: cytosol, m: membrane.